Targeting Growth Hormone Receptor to Overcome Therapy Resistance in Non-Small Cell Lung Cancer
Authors:
- Arshad AhmadAAArshad Ahmad
- Reetobrata BasuRBReetobrata Basu
- Caden FyffeCFCaden Fyffe
- Reece GeigerRGReece Geiger
- Christopher WalshCWChristopher Walsh
- Delany MintoDMDelany Minto
- Edward BrenyaEBEdward Brenya
- Amrutha Varshini AlurAAAmrutha Varshini Alur
- Sebastian J. C. M. M. NeggersSNSebastian J. C. M. M. Neggers
- John J. KopchickJKJohn J. Kopchick
Open Access
- 22 December 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 115
Abstract
Lung cancer (LC) remains the leading cause of cancer-related death in the United States despite advances in therapy. Growth hormone (GH) action has been implicated in tumor progression and therapy resistance across multiple cancers, but its role in LC, particularly non-small cell lung cancer (NSCLC), remains poorly defined. In cancer cells, GH promotes chemoresistance through upregulation of drug-efflux pumps, induction of epithelial-to-mesenchymal transition (EMT), and inhibition of apoptosis. Notably, GH receptor (GHR) expression is significantly elevated in NSCLC compared to normal lung tissue, suggesting a potential therapeutic opportunity. In this study, we investigated the impact of GH action on therapy resistance and tumor progression using integrated transcriptomic analyses and in vitro experiments. Analyses of transcriptomic data from NSCLC patients revealed that high tumoral GHR expression correlates with reduced overall survival, and with upregulation of genes involved in distinct therapy refractory pathways. Our in vitro studies demonstrated that GH promotes chemoresistance in NSCLC cell lines through activation of ABC transporters and EMT pathways, whereas GHR antagonism with the GH receptor antagonist, pegvisomant, effectively counteracts these effects and improves chemotherapy efficacy significantly. Together, our findings identify GHR signaling as a contributor to aggressive and therapy-resistant phenotypes in NSCLC in vitro and suggest that GHR antagonism may enhance chemotherapy sensitivity. These results provide a rationale for further in vivo and mechanistic studies to evaluate the therapeutic potential of targeting GHR in NSCLC.Keywords
Funding Information
- John J. Kopchick Molecular and Cellular Biology/Translational Biomedical Sciences Research Fellowship
This publication has 87 references indexed in Scilit:
- Apoptotic signaling pathways in bone metastatic lung cancer: a comprehensive analysisDiscover Oncology, 2024
- Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor InhibitorsJAMA Network Open, 2023
- Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancerCarbohydrate Polymers, 2021
- Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of agePituitary, 2021
- A novel peptide antagonist of the human growth hormone receptorJournal of Biological Chemistry, 2021
- ABC transporters as cancer drivers: Potential functions in cancer developmentBiochimica et Biophysica Acta (BBA) - General Subjects, 2019
- Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux PumpsDiscover Oncology, 2017
- Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegalyPituitary, 2016
- Growth hormone signaling pathwaysGrowth Hormone & IGF Research, 2016
- Structure and function of matrix metalloproteinases and TIMPsCardiovascular Research, 2006